Donanemab significantly slowed the decline of cognitive and functional abilities in people with early Alzheimer’s disease, according to top-line…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has approved Rexulti (brexpiprazole) to treat agitation associated with dementia due to…
Eli Lilly’s donanemab was found to work better than Aduhelm (aducanumab) in a biomarker study of people with…
Treatment with the experimental therapy BIIB080 led to long-term reductions in the levels of disease-associated tau protein in the brains…
Alzamend Neuro has completed the clinical portion of a Phase 2 trial testing AL001, an investigational formulation of lithium…
The U.S. Food and Drug Administration (FDA) has agreed to review a request to convert Leqembi’s (lecanemab) accelerated approval…
The U.S. Food and Drug Administration (FDA) will consider brexpiprazole to treat agitation in people with Alzheimer’s disease. The…
Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early…
Trametinib, an oral medication approved to treat certain cancers, improved cognition and neuronal health in a mouse model of…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of…